2022
AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)
Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s209-s210. DOI: 10.1016/s2152-2650(22)01214-9.Peer-Reviewed Original ResearchOverall response rateAcute myeloid leukemiaMorphologic leukemia-free stateOverall survivalComplete responseIDH2 inhibitorsMedian OSPartial remissionTargeted therapyEffective salvage therapyIncomplete count recoveryMedian overall survivalShorter median OSRetrospective cohort studyShorter overall survivalAcademic cancer centerFLT3-ITD mutationAlternative therapeutic strategiesSalvage therapyCohort studyCount recoveryInhibitor therapyTargeted agentsClinical efficacyCancer Center
2021
Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.
Dhakal P, Lyden E, Gundabolu K, Zeidan A, Loh K, Fisher A, Bhatt V. Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis. Journal Of Clinical Oncology 2021, 39: 6587-6587. DOI: 10.1200/jco.2021.39.15_suppl.6587.Peer-Reviewed Original ResearchSingle-agent therapyAcute promyelocytic leukemiaCommunity cancer centerMultiagent therapyAgent therapyCancer CenterReal-world practiceUninsured patientsClinical trialsComprehensive community cancer centerNational Cancer Database AnalysisMultiple logistic regression analysisFindings highlight disparitiesLower comorbidity indexThird of patientsAcademic cancer centerAppropriateness of treatmentHealth system factorsAcute myeloid leukemiaLogistic regression analysisUnknown therapyComorbidity indexGreater comorbidityMultiagent chemotherapyOverall survival